Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02923622
Other study ID # D161100005116002
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 23, 2016
Last updated October 1, 2016
Start date September 2016

Study information

Verified date September 2016
Source Xiyuan Hospital of China Academy of Chinese Medical Sciences
Contact n/a
Is FDA regulated No
Health authority China: Beijing Municipal Science and Technology Commission
Study type Observational

Clinical Trial Summary

Although patients of colorectal cancer use Traditional Chinese Medicine (TCM) herbal therapy extensively in China, no strong evidence exists to demonstrate the safety and survival outcomes of TCM herbal therapy combined with conventional western medicine for treatment of this disease. The purpose of this multi-center perspective cohort study is to evaluate the relationship between TCM herbal therapy and survival outcomes in patients with advanced colorectal cancer.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 384
Est. completion date
Est. primary completion date March 2020
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- histologically confirmed adenocarcinoma of the colon or rectum

- TNM classification of stage IV disease according to American Joint Committee on Cancer

- Between 18 and 80 years old

- Progression or inability undergone conventional chemotherapy (Conventional chemotherapy regimen containing fluorouracil, oxaliplatin, irinotecan based chemotherapy, and all the above regimen should be used before)

- Expected survival time is over 3 months

- Signed informed consent

Exclusion Criteria:

- serious non-malignant diseases such as heart, renal, and hepatic illnesses

- the presence of other types of malignancies

- The patients can not take medicine for intestinal obstruction

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Other:
Traditional Chinese medicine herbals
TCM herbal treatment based on TCM syndrome differentiation,without any anti tumor therapy in Western Medicine
Integrated traditional Chinese and Western medicine
TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
Western medicine
Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)

Locations

Country Name City State
China Oncology Department of Xiyuan hospital of China Academy of Chinese Medical Sciences Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijing Municipal Science & Technology Commission

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival 3 years Yes
Secondary Progress free survival 3 years Yes
Secondary Quality of life as assessed by FACT-C v4.0 3 years Yes
Secondary Tumor control rate 3 years Yes
Secondary TCM syndrome score 3 years Yes
Secondary Number of participants with treatment-related adverse events as assessed by Chinese version of CTCAE v4.0 3 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Recruiting NCT06200363 - A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer Phase 1
Completed NCT01723969 - Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Active, not recruiting NCT00309179 - A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors Phase 2
Completed NCT03699111 - Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Not yet recruiting NCT02826837 - LEAC-102 for Advanced Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05077839 - Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC Phase 2
Recruiting NCT04324476 - A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer Phase 2
Not yet recruiting NCT06369259 - Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer Phase 2
Completed NCT00707889 - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer Phase 2
Terminated NCT01271166 - Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer Phase 1
Completed NCT00386828 - Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial Phase 2
Recruiting NCT04764006 - Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study Phase 2
Active, not recruiting NCT04835324 - Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Active, not recruiting NCT02619435 - Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer Phase 2
Completed NCT01822444 - ANGIOPREDICT. ICORG 12-16, V3
Completed NCT00498407 - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer Phase 2
Recruiting NCT05731336 - A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
Active, not recruiting NCT04744831 - Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer Phase 2
Terminated NCT03311750 - Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer Phase 2